Company profile
Nemaura Medical Inc.
OTC: NMRD · Healthcare · Medical - Devices
#1054 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 56GM —SS 33
v0.1 · 25/100 weight · pillars only
↑ disclosure history, workforce scale · ↓ Piotroski F, net margin
Methodology →Revenue TTM
-$1.6M
Rev growth YoY (TTM)
-491.0%
Net income (FY)
-$14.1M
Employees
38
as of 2026-08-30
Market cap
$4.0k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$77.0k$77.0k2023
Net income-$14.1M-$14.1M2023
Operating income-$9.6M-$9.6M2023
Total assets$14.6M$14.6M2023
Liabilities$26.4M$26.4M2023
Equity-$11.8M-$11.8M2023
Revenue trend
FY2019 – FY2023 · USD
FY19
FY19
FY19
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Nemaura Medical Inc.’s revenue?
Nemaura Medical Inc. booked $77.0k in FY2023 revenue, contracting 85% year over year — slower than 89% of Healthcare companies we track, at a -18358.0% net margin.
Peers · Healthcare
Sera Prognostics, Inc.41DXebra Brands Ltd.——Imaging Dynamics Company Ltd.31DRegeneRx Biopharmaceuticals, Inc.——Sky Century Investment, Inc.28DAclarion, Inc.36DNeighbors
New York →Key facts
CEODewan Fazlul Hoque Chowdhury
SectorHealthcare
IndustryMedical - Devices
HeadquartersNew York City, NY
ExchangeOTC: NMRD
Employees38
IPO date2018-02-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.